Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 13
Opinion
Video
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Author(s):
Max Kates, MD, discusses how newer therapies for BCG-unresponsive NMIBC may have better long-term cost-effectiveness despite higher initial costs, emphasizing the importance of leveraging patient assistance programs, copay cards, and foundation support to ensure treatment access while using cost comparison tools to help patients make informed decisions.
- Annual cost analyses suggest that some newer therapies may have higher up-front costs but can be more economical in the long run due to fewer recurrences and less frequent administration.
- How does the cost-effectiveness of treatments, particularly in relation to newer therapies, influence your recommendations for patients with BCG-unresponsive NMIBC?
- Are there specific tools or resources you rely on to help assess and present these options to patients?
- What financial assistance or patient support programs (eg, copay cards, patient assistance foundations, or programs) have you found most helpful in ensuring that patients can afford and access the right treatments, and how do you guide patients in utilizing these resources?
Related Videos
Related Content
